BLU-667 (Pralsetinib)

BLU-667 (Pralsetinib) is a highly potent and selective, next generation RET inhibitor with IC₅₀ of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion. In vivo, BLU-667 potently inhibits growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2.